HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Test (opens in a new window) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kostakoglu, L. Articles by Goldsmith, S. J. Search for Related Content PubMed PubMed Citation Articles by Kostakoglu, L. Articles by Goldsmith, S. J. Related Collections Nuclear Medicine

Clinical Role of FDG PET in Evaluation of Cancer Patients¹

¹ From the Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Cornell Medical Center, 525 E 68th St, Starr No. 221, New York, NY 10021 (L.K., S.J.G.); and the Division of Nuclear Medicine, Department of Radiology, Hackensack University Medical Center, Hackensack, NJ (H.A.). Received April 25, 2002; revision requested August 5 and received October 7; accepted October 8. H.A. has given lectures sponsored by CTI (Knoxville, Tenn), PETNET (Knoxville, Tenn), and Alliance Imaging (Anaheim, Calif) on use of PET. Address correspondence to L.K. (e-mail: lak2005@med.cornell.edu).

Positron emission tomography (PET) is a diagnostic imaging technique that allows identification of biochemical and physiologic alterations in tumors. Use of PET performed with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) significantly improves the accuracy of tumor imaging. In terms of oncologic applications, FDG PET has already gained widespread acceptance in the initial staging of cancer, management of recurrent cancer, and monitoring the response to therapy. With conventional imaging modalities, size criteria are used to distinguish between benign and malignant disease in lymph nodes; conversely, FDG PET is based on identification of fundamental aspects of tumor metabolism. FDG uptake in tumors is proportional to the metabolic rate of viable tumor cells, which have an increased demand for glucose. The high sensitivity and high negative predictive value of FDG PET in most malignant tumors enable this technique to play an even greater role in tumor management at initial staging and follow-up.

© RSNA, 2003

Index Terms: Fluorine, radioactive • Neoplasms, PET, _**.12163², _**.30 • Neoplasms, staging • Positron emission tomography (PET), _**.12163

This article has been cited by other articles:

				S. Belakhlef, C. Church, A. Hays, R. Fraser, and S. Lakhanpal Quantitative Assessment of the Influence of Location, Internal Temperature, Idle Time, and Normalization on the Sensitivity of a Mobile PET/CT Scanner J. Nucl. Med. Technol., September 1, 2008; 36(3): 147 - 150. [Abstract] [Full Text] [PDF]

				K. Kitajima, K. Murakami, E. Yamasaki, I. Fukasawa, N. Inaba, Y. Kaji, and K. Sugimura Accuracy of 18F-FDG PET/CT in Detecting Pelvic and Paraaortic Lymph Node Metastasis in Patients with Endometrial Cancer Am. J. Roentgenol., June 1, 2008; 190(6): 1652 - 1658. [Abstract] [Full Text] [PDF]

				J. Burrill, C. J. Williams, G. Bain, G. Conder, A. L. Hine, and R. R. Misra Tuberculosis: A Radiologic Review RadioGraphics, September 1, 2007; 27(5): 1255 - 1273. [Abstract] [Full Text] [PDF]

				A. B. Elaini, S. K. Shetty, V. M. Chapman, D. V. Sahani, G. W. Boland, A. T. Sweeney, M. M. Maher, J. T. Slattery, P. R. Mueller, and M. A. Blake Improved Detection and Characterization of Adrenal Disease with PET-CT RadioGraphics, May 1, 2007; 27(3): 755 - 767. [Abstract] [Full Text] [PDF]

				R. Kono, K. Fujimoto, H. Terasaki, N. L. Muller, S. Kato, J. Sadohara, N. Hayabuchi, and S. Takamori Dynamic MRI of Solitary Pulmonary Nodules: Comparison of Enhancement Patterns of Malignant and Benign Small Peripheral Lung Lesions Am. J. Roentgenol., January 1, 2007; 188(1): 26 - 36. [Abstract] [Full Text] [PDF]

				O. Israel and A. Kuten Early Detection of Cancer Recurrence: 18F-FDG PET/CT Can Make a Difference in Diagnosis and Patient Care J. Nucl. Med., January 1, 2007; 48(1_suppl): 28S - 35S. [Abstract] [Full Text] [PDF]

				H. B. Prabhakar, D. V. Sahani, A. J. Fischman, P. R. Mueller, and M. A. Blake Bowel Hot Spots at PET-CT RadioGraphics, January 1, 2007; 27(1): 145 - 159. [Abstract] [Full Text] [PDF]

				M. A. Blake, A. Singh, B. N. Setty, J. Slattery, M. Kalra, M. M. Maher, D. V. Sahani, A. J. Fischman, and P. R. Mueller Pearls and Pitfalls in Interpretation of Abdominal and Pelvic PET-CT RadioGraphics, September 1, 2006; 26(5): 1335 - 1353. [Abstract] [Full Text] [PDF]

				R. L. Korn, A. M. Yost, C. C. May, E. R. Kovalsky, K. M. Orth, T. A. Layton, and D. Drumm Unexpected focal hypermetabolic activity in the breast: significance in patients undergoing 18F-FDG PET/CT. Am. J. Roentgenol., July 1, 2006; 187(1): 81 - 85. [Abstract] [Full Text] [PDF]

				K.-H. Lee, B.-H. Ko, J.-Y. Paik, K.-H. Jung, Y. S. Choe, Y. Choi, and B.-T. Kim Effects of Anesthetic Agents and Fasting Duration on 18F-FDG Biodistribution and Insulin Levels in Tumor-Bearing Mice J. Nucl. Med., September 1, 2005; 46(9): 1531 - 1536. [Abstract] [Full Text] [PDF]

				M. B. McCarville, R. Christie, N. C. Daw, S. L. Spunt, and S. C. Kaste PET/CT in the Evaluation of Childhood Sarcomas Am. J. Roentgenol., April 1, 2005; 184(4): 1293 - 1304. [Abstract] [Full Text] [PDF]

				V. Kapoor, M. B. Fukui, and B. M. McCook Role of 18FFDG PET/CT in the Treatment of Head and Neck Cancers: Principles, Technique, Normal Distribution, and Initial Staging Am. J. Roentgenol., February 1, 2005; 184(2): 579 - 587. [Full Text] [PDF]

				V. Kapoor, M. B. Fukui, and B. M. McCook Role of 18FFDG PET/CT in the Treatment of Head and Neck Cancers: Posttherapy Evaluation and Pitfalls Am. J. Roentgenol., February 1, 2005; 184(2): 589 - 597. [Full Text] [PDF]

				O. Israel, M. Mor, L. Guralnik, N. Hermoni, D. Gaitini, R. Bar-Shalom, Z. Keidar, and R. Epelbaum Is 18F-FDG PET/CT Useful for Imaging and Management of Patients with Suspected Occult Recurrence of Cancer? J. Nucl. Med., December 1, 2004; 45(12): 2045 - 2051. [Abstract] [Full Text] [PDF]

				M. Torabi, S. L. Aquino, and M. G. Harisinghani Current Concepts in Lymph Node Imaging J. Nucl. Med., September 1, 2004; 45(9): 1509 - 1518. [Abstract] [Full Text] [PDF]

				L. Kostakoglu, R. Hardoff, R. Mirtcheva, and S. J. Goldsmith PET-CT Fusion Imaging in Differentiating Physiologic from Pathologic FDG Uptake RadioGraphics, September 1, 2004; 24(5): 1411 - 1431. [Abstract] [Full Text] [PDF]

				V. Kapoor, B. M. McCook, and F. S. Torok An Introduction to PET-CT Imaging RadioGraphics, March 1, 2004; 24(2): 523 - 543. [Abstract] [Full Text] [PDF]

				H. Agress Jr and B. Z. Cooper Detection of Clinically Unexpected Malignant and Premalignant Tumors with Whole-Body FDG PET: Histopathologic Comparison Radiology, February 1, 2004; 230(2): 417 - 422. [Abstract] [Full Text] [PDF]

				P. J. Woodward, K. Hosseinzadeh, and J. S. Saenger From the Archives of the AFIP: Radiologic Staging of Ovarian Carcinoma with Pathologic Correlation RadioGraphics, January 1, 2004; 24(1): 225 - 246. [Abstract] [Full Text] [PDF]